Skip to main content

Merck to buy Prometheus Biosciences for $10.8 billion

Merck & Co. Inc. announced Sunday a deal to acquire Prometheus Biosciences Inc. for $200 a share, or about $10.8 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.